hsa-mir-625: Hsa-mir-625 is a microRNA that has been found to be down-regulated in various conditions, including Alzheimer's disease (AD) [PMC3205057]. It is one of the microRNAs predicted to target multiple genes associated with AD [PMC9312389]. Hsa-mir-625 has also been identified as one of the miRNAs that can be used to distinguish different types of lymphomas [PMC4335255]. Additionally, it has been found to be differentially expressed in various cancers, including breast cancer [PMC6412941] and pancreatic cancer [PMC7942015]. The upregulation of hsa-mir-625 has been investigated for its effect on apoptosis and proliferation in a specific cell line [PMC9375600]. In human oocytes, hsa-mir-625 was found to be up-regulated in mature oocytes compared to immature ones [PMC4919285]. The variant deletion allele of hsa-mir-625 has been associated with changes in its minimum free energy (MFE) and potential target sites for other miRNAs have been identified within its sequence [PMC3444488] [PMC4008537]. Hsa-mir-625 is also mentioned as one of the miRNA precursors with previously unreported antisense transcripts [PMC3722126]. Finally, it has been identified as one of the RNA molecules transferred from pancreatic cancer cells to osteoblasts via small extracellular vesicles (sEVs) for intercellular communication [PMC8056276].

MIR625: MIR625 is a microRNA that is down-regulated when Dicer is down-regulated, leading to decreased production of several miRNAs [PMC3316564]. Decreased expression of MIR625 has been observed in colorectal carcinoma [PMC7137242]. In colorectal carcinoma, MIR625 is associated with decreased survival rates [PMC7137242].